Appointment of Senior Croda VP as Board Advisor

SkinBioTherapeutics PLC

29 July 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Senior Croda Vice President joins SkinBioTherapeutics as
Cosmetic Science / Customer Alliances Advisor to the Board

Recognised as one of Croda's senior researchers in cosmetic ingredients

29 July 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces the appointment of Dr Surinder 'Dass' Chahal as Cosmetic Science / Customer Alliances Advisor to the Board.

Dr Chahal has been closely involved with SkinBioTherapeutics since the signing of the commercial and manufacturing agreement in November 2019 between SkinBioTherapeutics and Croda's Consumer Care division, Sederma, which is the specialist in bioactive ingredients for the cosmetics industry. His role will be the interface with Croda as the partnership moves into commercialisation. He will also advise on cosmetic science and assist the Company in strategic alliances with other multinationals. 

Dr Chahal's career at Croda International PLC (Croda or the Group), one of the world's leading speciality ingredients manufacturers, has spanned over 37 years. He joined Croda in 1987, initially leading cosmetic protein innovation at the Group, then moved onto a variety of roles including Enterprise Technologies which involved open innovation, technology investment, and he went on to establish Croda's biotechnology research group. In 2014 he was appointed to Croda's Global Personal Care Board as Vice President Research & Development, then was appointed as VP Long-Term Innovation covering strategic research and technology acquisition.

He rose to become part of the Long-Term Innovation group as VP Customer Alliances (Technology Development) working as part of the CSO's senior technology team across all Croda businesses. He is recognised as one of Croda's senior researchers in the field of cosmetic ingredients.

Dr Chahal has a B.Sc. (Hons) Chemistry and a PhD in Chemistry and Chemical technology from the University of Bradford.

Martin Hunt, Chairman of SkinBioTherapeutics, said:

"We are absolutely delighted to have Dass act as a senior advisor to the Board. He has had a distinguished career at Croda across a variety of roles, each of which enables him to provide valuable insight and advice to us as we develop and commercialise our various business pillars. We have got to know him through our partnership with Croda and he has been instrumental in building the strong relationship that we have with both the Croda and Sederma teams. We are very much looking forward to having him as part of the advisory team."

Dr Chahal added:

"I have been a great supporter of the team at SkinBioTherapeutics ever since I first saw the Skinbiotix technology and realised its potential across multiple segments of skin healthcare. The Company may be relatively small compared to Croda, but it has achieved a tremendous amount in a short period. As I complete my career at Croda, I am delighted to still be involved with the SkinBioTherapeutics team and its technology."  

-Ends-

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For more information please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	[phone]
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)	[phone]
Vigo Consulting (financial press) Rozi Morris	[phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

 

END